NCT02511106 · OUTCOME

Disease Free Survival (DFS) Rate at 2, 3 and 5 Years

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy. · Source last updated 2026-03-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: Percentage of participants
Interval / dispersion: 95% Confidence Interval
Time frame: Up to approximately 5 years after the first patient is randomized (maximum follow up of 70 months). DFS rate at 2 years (%), 3 years (%) and 5 years (%) are presented.

What was measured

Defined as the percentage of patients alive and disease free at 2, 3 and 5 years, respectively, estimated from Kaplan Meier plots of the primary endpoint of DFS.

Analysis population: Full analysis set (FAS) stage IB-IIIA patients

Groups in this outcome

AZD9291 80mg Tablet

Taken once daily

Placebo Tablet

Taken once daily

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
AZD9291 80mg Tablet	339
Placebo Tablet	343

Reported measurements

DFS rate at 2 years (%)

Values in Percentage of participants · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
AZD9291 80mg Tablet	90.1	Not reported	86.2	92.9	Not reported
Placebo Tablet	54.5	Not reported	49.0	59.7	Not reported

DFS rate at 3 years (%)

Values in Percentage of participants · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
AZD9291 80mg Tablet	84.5	Not reported	79.9	88.1	Not reported
Placebo Tablet	44.4	Not reported	39.0	49.7	Not reported

DFS rate at 5 years (%)

Values in Percentage of participants · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
AZD9291 80mg Tablet	60.9	Not reported	53.1	67.8	Not reported
Placebo Tablet	33.6	Not reported	28.0	39.2	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
86.2
upper Limit
92.9
value
90.1
group Id
OG001
lower Limit
49.0
upper Limit
59.7
value
54.5
title
DFS rate at 2 years (%)
categories
measurements
group Id
OG000
lower Limit
79.9
upper Limit
88.1
value
84.5
group Id
OG001
lower Limit
39.0
upper Limit
49.7
value
44.4
title
DFS rate at 3 years (%)
categories
measurements
group Id
OG000
lower Limit
53.1
upper Limit
67.8
value
60.9
group Id
OG001
lower Limit
28.0
upper Limit
39.2
value
33.6
title
DFS rate at 5 years (%)

denoms

counts
group Id
OG000
value
339
group Id
OG001
value
343
units
Participants

description

Defined as the percentage of patients alive and disease free at 2, 3 and 5 years, respectively, estimated from Kaplan Meier plots of the primary endpoint of DFS.

dispersion Type

95% Confidence Interval

groups

description
Taken once daily
id
OG000
title
AZD9291 80mg Tablet
description
Taken once daily
id
OG001
title
Placebo Tablet

param Type

NUMBER

population Description

Full analysis set (FAS) stage IB-IIIA patients

reporting Status

POSTED

time Frame

Up to approximately 5 years after the first patient is randomized (maximum follow up of 70 months). DFS rate at 2 years (%), 3 years (%) and 5 years (%) are presented.

title

Disease Free Survival (DFS) Rate at 2, 3 and 5 Years

type

SECONDARY

unit Of Measure

Percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice